Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Canada sets out COVID-19 plans to vaccinate a majority by September 2021

Following Prime Minister Justin Trudeau’s announcement of Canada’s vaccination schedules; James Spencer, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view: “With the recent announcement of several potential COVID-19 vaccines one after another, countries around the world have been scrambling to put together their vaccine plans. “Trudeau stated that he expects […]
Read more

Novartis’ registration of head-to-head psoriatic arthritis clinical trial begins the battle for second place,

Novartis recently registered a Phase III psoriatic arthritis (PsA) clinical trial of its IL-17 inhibitor Cosentyx (secukinumab) compared against Johnson & Johnson’s Stelara (ustekinumab). The registration of this trial demonstrates Novartis’ continued efforts to solidify its position in an increasingly crowded market, according to GlobalData, a leading data and analytics company. Tiffany Chan, Immunology Analyst […]
Read more

Bladder cancer therapeutics market projected to exceed $5.5bn by 2028

The bladder cancer therapeutics market was valued at $670m in 2018 across the seven major markets (7MM*) and is expected to grow exponentially at a compound annual growth rate (CAGR) of 23.6% – accruing slightly less than $5.6bn in 2028, according to GlobalData, a leading data and analytics company. GlobalData’s latest report, ‘Bladder Cancer Opportunity […]
Read more

Following landmark approval, Pfizer and BioNTech can use UK as test bed for cold chain distribution

Following the news that Pfizer/BioNTech’s COVID-19 vaccine BNT162b2 received emergency use approval from UK health authorities; Philipp Rosenbaum, PhD, Senior Infectious Diseases Analyst at GlobalData, a leading data and analytics company, offers his view: “The UK represents an ideal test bed for the delivery of Pfizer’s vaccine. The country’s small size, dense population and strong […]
Read more

China pulls ahead in immuno-oncology with highest PD-1/PD-L1 combination clinical trials growth, reveals GlobalData

China recorded the highest year-on-year increase in the number of clinical trials initiated investigating PD-1/PD-L1 targeted combination immuno-oncology therapies across the eight major markets (8MM*) in 2020, according to GlobalData, a leading data and analytics company. In 2020, the US emerged as the leading market in industry-sponsored initiated clinical trials for PD-1/PD-L1 targeted combination therapies […]
Read more

Phase III data for Omecamtiv Mecarbil and Finerenone demonstrates reduced risk of cardiovascular events at AHA conference

A record number of late-breaking trials were submitted to the Annual Scientific Sessions of the American Heart Association (AHA) this year and unsurprisingly, a key theme of this year’s conference was the COVID-19 pandemic, says GlobalData, a leading data and analytics company. Fiona Chisholm, Managing Analyst at GlobalData, comments: “One notable study, which analyzed records […]
Read more

FDA approval of Provention Bio’s Teplizumab could bring first disease-modifying therapy to type 1 diabetes space

If Provention Bio’s rolling Biologic License Application (BLA) submission to the FDA for teplizumab is approved, teplizumab will be the first disease-modifying therapy for type 1 diabetes (T1D). Teplizumab is one of the first therapeutics to demonstrate a disease-modifying effect for T1D. As it is a prevention therapy, it is expected to encourage early screening […]
Read more
1 … 76 77 78 79 80 … 111